{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:18:13Z","timestamp":1759331893205},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[1995]]},"DOI":"10.1007\/bf00156419","type":"journal-article","created":{"date-parts":[[2004,11,6]],"date-time":"2004-11-06T06:02:56Z","timestamp":1099720976000},"page":"43-49","source":"Crossref","is-referenced-by-count":24,"title":["Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU"],"prefix":"10.1007","volume":"19","author":[{"given":"Hesamodin","family":"Borhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholam A.","family":"Peyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad H.","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0002-9394(82)90239-2","volume":"94","author":"MS Blumenkranz","year":"1982","unstructured":"Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 1982; 94: 458?67.","journal-title":"Am J Ophthalmol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0161-6420(84)34318-4","volume":"91","author":"M Blumenkranz","year":"1984","unstructured":"Blumenkranz M, Hernandez E, Ophir A, Norton EWD. 5-fluorouracil: New applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91:122?30.","journal-title":"Ophthalmology"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/02713689109003447","volume":"10","author":"CN Koutsandrea","year":"1991","unstructured":"Koutsandrea CN, Miceli MV, Peyman GA, Farahat HG, Niesman MR. Ciprofloxacin and dexamethasone inhibit the proliferation of human retinal pigment epithelial cells in culture. cuit Eye Res 1991; 10: 249?58.","journal-title":"cuit Eye Res"},{"key":"CR4","first-page":"2160","volume":"33","author":"EP Chen","year":"1992","unstructured":"Chen EP, Steinhorst UH, Samsa GP, Saloupis PT, Hatchell DL. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33: 2160?4.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR5","first-page":"719","volume":"26","author":"P Wiedemann","year":"1985","unstructured":"Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci 1985; 26: 719?25.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR6","first-page":"845","volume":"14","author":"A Barrada","year":"1983","unstructured":"Barrada A, Peyman GA, Greenberg D, Stelmack T, Fiscella R. Toxicity of antineoplastic drugs in vitrectomy infusion fluids. Ophthalmic Surg 1983; 14: 845?7.","journal-title":"Ophthalmic Surg"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jop.1991.7.27","volume":"7","author":"VKW Wong","year":"1991","unstructured":"Wong VKW, Shapourifar-Tehrani S, Kitada S, Choo PH, Lee DA. Inhibition of rabbit ocular fibroblast proliferation by 5-fluorouracil and cytosine arabinoside. J Ocular Pharmacol 1991;7: 27?39.","journal-title":"J Ocular Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0002-9394(80)90239-1","volume":"89","author":"Y Tano","year":"1980","unstructured":"Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89: 131?6.","journal-title":"Am J Ophthalmol"},{"key":"CR9","first-page":"522","volume":"34","author":"JJ Araiz","year":"1993","unstructured":"Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FI. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1993; 34: 522?30.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000267111","volume":"23","author":"A Ophir","year":"1991","unstructured":"Ophir A. Further observations on the prevention of experimental proliferative vitreo-retinopathy by 5-fluorouracil. Ophthalmic Res 1991; 23: 128?32.","journal-title":"Ophthalmic Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0002-9394(83)90452-X","volume":"96","author":"WH Stern","year":"1983","unstructured":"Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 1983; 96: 33?42.","journal-title":"Am J Ophthalmol"},{"key":"CR12","first-page":"200","volume-title":"A pharmacologic approach to non-neoplastic intraocular proliferation. ARVO Supplement to Invest Ophthalmol Vis Sci","author":"M Blumenkranz","year":"1981","unstructured":"Blumenkranz M, Ophir A, Claflin A. A pharmacologic approach to non-neoplastic intraocular proliferation. ARVO Supplement to Invest Ophthalmol Vis Sci. St. Louis: CV Mosby 1981:200."},{"key":"CR13","first-page":"2891","volume":"32","author":"KK Assil","year":"1991","unstructured":"Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy: Rabbit model using antimetabolite encapsulated liposome. Invest Ophthalmol Vis Sci 1991; 32: 2891?7.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-9394(83)90453-1","volume":"96","author":"WH Stern","year":"1983","unstructured":"Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, Fisher SK. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 1983; 96:43?51.","journal-title":"Am J Ophthalmol"},{"key":"CR15","first-page":"1226","volume":"23","author":"C Heidelberger","year":"1963","unstructured":"Heidelberger C, Ansfield FJ. Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 1963; 23:1226?43.","journal-title":"Cancer Res"},{"key":"CR16","first-page":"677","volume-title":"Retinal detachment","author":"RG Michels","year":"1990","unstructured":"Michels RG, Wilkinson CP, Rice TA. Complicated types of retinal detachment. In: Michels RG, Wilkinson CP, Rice TA, editors. Retinal detachment. St Louis: CV Mosby 1990: 677."},{"key":"CR17","first-page":"1489","volume":"34","author":"MH Rahimy","year":"1993","unstructured":"Rahimy MH, Borhani H, Peyman GA. Controlled-release delivery system for growth factors: Implications for retinal degenerative diseases. Invest Ophthalmol Vis Sci 1993; 34 Suppl: 1489.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR18","first-page":"1488","volume":"34","author":"H Borhani","year":"1993","unstructured":"Borhani H, Rahimy MH, Peyman GA. Sustained release of 5-FU from bioerodible-matrix delivery for intraocular application: In vitro and in vivo evaluation. Invest Ophthalmol Vis Sci 1993; 34 Suppl: 1488.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR19","first-page":"1490","volume":"34","author":"S Chin","year":"1993","unstructured":"Chin S, Rahimy MH, Peyman GA. Bioerodible ganciclovir delivery system for intraocular application: In vitro kinetic evaluation. Invest Ophthalmol Vis Sci 1993; 34 Suppl: 1490.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR20","first-page":"1493","volume":"34","author":"D Yang","year":"1993","unstructured":"Yang D, Rahimy DH, Peyman GA. Low molecular weight poly(caprolactone) and poly(DL-Lactide) prepared by hydrolysis and their applications as biodegradable carriers for drug delivery. Invest Ophthalmol Vis Sci 1993; 34 Suppl: 1493.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR21","first-page":"1599","volume":"26","author":"PL Mayerson","year":"1985","unstructured":"Mayerson PL, Hall MO, Clark V, Abrams T. An improved method for isolation and culture of rat retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1985; 26: 1599?609.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0002-9394(14)77369-6","volume":"93","author":"DM Fastenberg","year":"1982","unstructured":"Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ. A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 1982; 93: 559?64.","journal-title":"Am J Ophthalmol"},{"key":"CR23","first-page":"312","volume-title":"Nonparametric statistics for the behavioral sciences","author":"S Siegel","year":"1956","unstructured":"Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill 1956: 312."},{"key":"CR24","first-page":"580","volume":"26","author":"MS Shapiro","year":"1985","unstructured":"Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 1985; 26: 580?3.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR25","first-page":"187","volume":"18","author":"DA Lee","year":"1987","unstructured":"Lee DA, Hersh P, Kersten D, Melamed S. Complications of subconjunctival 5-fluorouracil following glaucoma filtering surgery. Ophthalmic Surg 1987; 18: 187?90.","journal-title":"Ophthalmic Surg"},{"key":"CR26","first-page":"358","volume":"20","author":"KR Liu","year":"1989","unstructured":"Liu KR, Peyman GA, She SC, Niesman MR, Khoobehi B. Reduced toxicity of intravitreally injected liposomeencapsulated cytarabine. Ophthalmic Surg 1989; 20: 358?61.","journal-title":"Ophthalmic Surg"},{"key":"CR27","first-page":"893","volume":"28","author":"M Barza","year":"1987","unstructured":"Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987; 28: 893?900.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR28","first-page":"907","volume":"28","author":"WH Stern","year":"1987","unstructured":"Stern WH, Heath TD, Lewis GP, Guerin CJ, Erickson PA, Lopez W et al. Clearance and localization of intravitreal liposomes in the aphakic vitrectomized eye. Invest Ophthalmol Vis Sci 1987; 28: 907?11.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archopht.1992.01080140111037","volume":"110","author":"TJ Smith","year":"1992","unstructured":"Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992; 110: 255?8.","journal-title":"Arch Ophthalmol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archopht.1992.01080140044023","volume":"110","author":"GE Sanborn","year":"1992","unstructured":"Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirusretinitis: Use of an intravitreal device. Arch Ophthalmol 1992; 110: 188?95.","journal-title":"Arch Ophthalmol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archopht.1994.01090150137036","volume":"112","author":"PE Rubsamen","year":"1994","unstructured":"Rubsamen PE, Davis PA, Hernandez E, O'Grady GE, Cousins SW. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 1994; 112:407?13.","journal-title":"Arch Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00156419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00156419\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00156419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:25:13Z","timestamp":1554290713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00156419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995]]}},"alternative-id":["BF00156419"],"URL":"https:\/\/doi.org\/10.1007\/bf00156419","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995]]}}}